Swiss biotech sidesteps Covid with record investment
The Covid-19 pandemic limited funding in the Swiss biotech sector last year.
Copyright 2020 The Associated Press. All Rights Reserved
Swiss biotechnology companies invested a record CHF2.6 billion ($2.7 billion) into research last year despite most concentrating their efforts away from the coronavirus pandemic.
This content was published on
1 minute
swissinfo.ch/mga
Português
pt
Biotecnologia suíça consegue investimento recorde apesar da Covid
Research was instead focused on areas such as immuno-oncology, neurology and emerging areas such as cell-based therapies, according to the annual Swiss Biotech Report from consultancy group EY Switzerland.
The industry achieved sales of CHF6.7 billion in 2021, up from CHF4.9 billion the year before. But the global pandemic had a surprisingly detrimental effect on the health of the Swiss biotech industry.
Funding fell away slightly to CHF3.3 billion as investors concentrated on fighting the Covid-19 pandemic. “As a result, some companies have not received the financing they may need to survive,” said Frederik Schmachtenberg, life sciences expert at EY Switzerland, on Tuesday.
Some three to five percent of small biotech companies fell into severe financial difficulties or had to shut down, said Michael Altorfer, CEO of the Swiss Biotech Association, on Tuesday.
“Over the past year, I’ve been far more concerned about the potential financial problems of individual companies,” he said.
But the report authors hope that funding will return to other research areas as the global pandemic looks to be coming under control this year.
Switzerland has some 323 biotech companies, employing around 17,855 people, which is a 9.5% increase in employees from 2020.
Train vs plane: would you take a direct train between London and Geneva?
Eurostar is planning to run direct trains from Britain to Germany and Switzerland from the early 2030s. Would you favour the train over the plane? If not, why not?
This content was published on
Consumer prices picked up again in June in Switzerland, after briefly dipping into negative territory the previous month.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Looming bacterial pandemic triggers debate over how to pay for new antibiotics
This content was published on
Few big pharmaceutical companies have a stake in new antibiotics research. Financial incentives could help, but they are controversial.
Switzerland approves its first protein-based Covid vaccine
This content was published on
The Swiss medical regulator has approved the Nuvaxovid vaccine for adults making it the fourth Covid-19 vaccine authorised in the country.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.